Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01727141 · ClinicalTrials.gov registry record · Phase 3
A 12 Week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation.
A Phase 3 study of Chronic Obstructive Pulmonary Disease (COPD), sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,042
- Enrollment target
- 20
- Study locations
NCT01727141 is a Phase 3 study of Chronic Obstructive Pulmonary Disease (COPD) that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 1,042 participants, above the 622-participant average among 36 other Chronic Obstructive Pulmonary Disease (COPD) trials with a reported enrollment target (68% higher). The trial reports 20 study locations across 5 states.
The verdict
NCT01727141, a Phase 3 study of Chronic Obstructive Pulmonary Disease (COPD), has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,042 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will assess the efficacy, safety and tolerability of QVA149 in patients with moderate to severe airflow limitation.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG NVA237
- DRUG QVA149
- DRUG QAB149
Study Locations (20)
California
- Novartis Investigative Site - Fountain Valley
- Novartis Investigative Site - Fullerton
- Novartis Investigative Site - Huntington Beach
- Novartis Investigative Site - Montclair
- Novartis Investigative Site - Orange
- Novartis Investigative Site - Orangevale
- Novartis Investigative Site - Paramount
- Novartis Investigative Site - Riverside
- Novartis Investigative Site - Roseville
- Novartis Investigative Site - Sacramento
- Novartis Investigative Site - Sacramento
- Novartis Investigative Site - Sacramento
- Novartis Investigative Site - San Diego
- Novartis Investigative Site - Torrance
Alabama
- Novartis Investigative Site - Birmingham
- Novartis Investigative Site - Montgomery
Arizona
- Novartis Investigative Site - Mesa
- Novartis Investigative Site - Phoenix
Colorado
- Novartis Investigative Site - Wheat Ridge
Connecticut
- Novartis Investigative Site - Waterbury
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,042 participants |
| Start Date | 2012-11 |
| Est. Completion | 2014-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01727141
The ClinicalTrials.gov registry entry for NCT01727141 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,042 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 622-participant average among 36 other Chronic Obstructive Pulmonary Disease (COPD) trials with a reported enrollment target (68% higher). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Obstructive Pulmonary Disease (COPD) appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.
NCT01727141 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Alabama, Arizona.
Frequently Asked Questions
What is clinical trial NCT01727141 about?
NCT01727141 is a clinical study titled "A 12 Week Treatment, Multi-center, Randomized, Double-blind, Parallel-group, Placebo and Active Controlled Study to Assess the Efficacy, Safety, and Tolerability of Indacaterol Maleate / Glycopyrronium Bromide in COPD Patients With Moderate to Severe Airflow Limitation.". This study will assess the efficacy, safety and tolerability of QVA149 in patients with moderate to severe airflow limitation.
What is the current status of trial NCT01727141?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,042 participants. The study started on 2012-11. Estimated completion is 2014-02.
What conditions does trial NCT01727141 study?
This clinical trial studies the following conditions: Chronic Obstructive Pulmonary Disease (COPD).
What interventions are being tested in trial NCT01727141?
The interventions under investigation include: Placebo (DRUG), NVA237 (DRUG), QVA149 (DRUG), QAB149 (DRUG).
Who is sponsoring clinical trial NCT01727141?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01727141 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Obstructive Pulmonary Disease (COPD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Multi-Center Clean Air Randomized Controlled Trial in COPD
RECRUITING · Phase 3
-
A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease
RECRUITING · Phase 3
-
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
RECRUITING · Phase 3
-
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)
RECRUITING · Phase 3
-
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations.
ACTIVE NOT RECRUITING · Phase 3
-
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.